Stock Watch: Novo Edges Ahead Of Lilly In GLP-1 Agonist Battle

Gold Only Glitters If You Can Manufacture It

The sales performances of the GLP-1 agonists dominated the earnings of Novo Nordisk and Lilly, with both stocks hitting 52-week highs after their results. But one moved ahead of the other in an important strategic bottleneck.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

For at least the last six months, the two leading contenders in the battle for GLP-1 agonist supremacy in diabetes and obesity – Novo Nordisk A/S and Eli Lilly and Company – reported their quarterly results in the same week or even on the same day. (Also see "Stock Watch: Where Novo And Lilly Lead, Others Follow" - Scrip, 21 November, 2023.) With Lilly reporting after Novo and many US funds confined to holding only US-domiciled stocks, the cumulatively good clinical and financial news from both companies seemed to benefit Lilly the most. But in fourth-quarter and full-year 2023 earnings season, Novo reported almost a week before Lilly in what appeared to be a successful move to establish clear blue reporting water between the two.

[Sidebar#SC149720]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Stock Watch

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.